Company stock · NASDAQ NMS - GLOBAL MARKET · USD

CTNM

Contineum Therapeutics Inc

—

Price unavailable — company details still show below

Industry: Pharmaceuticals
Market value: $312.6 million
Number of shares: 37.6 million
Country: US
Went public: Apr 5, 2024
Exchange: NASDAQ NMS - GLOBAL MARKET
Website: contineum-tx.com
Next earnings: 2026-11-11 · analysts’ expected profit per share $-0.46

Compare →Earnings calendar →

Price chart Pro

Loading chart…

Company briefing

What CTNM is

Plain English context — why the name shows up in the news, and what to watch next.

In plain English

Contineum Therapeutics Inc. develops and sells prescription medicines, focusing on a depression drug called MOONLIGHT‑1 that is licensed…

Recent headlines

Live company news for CTNM — each headline includes a ClearTape brief in plain English; open the original for the full story.

Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30In brief
Jones Trading keeps a Buy rating on Contineum Therapeutics and lifts its target price to $30 from $24. The move reflects confidence in the company’s prospects.
Benzinga · Oct 15, 2026
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayIn brief
Several analysts downgraded Contineum Therapeutics, cutting its target price. The downgrade is part of a broader list of five top downgrades for the day.
Benzinga · Oct 14, 2026
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14In brief
Baird analyst Joel Beatty lowered Contineum Therapeutics’ rating to Neutral and cut the target price to $14 from $19. The change signals a more cautious view.
Benzinga · Oct 14, 2026
Johnson & Johnson: Keep Calm And Hold OnIn brief
Johnson & Johnson was downgraded to a Hold due to mixed fundamentals and regulatory challenges. The rating suggests a neutral stance on the stock.
SeekingAlpha · Oct 13, 2026
BMY Reports Mixed Phase III Trial Results, Stock DownIn brief
Bristol Myers Squibb reported mixed Phase III results for admilparant in IPF, while RYZ101 achieved a significant win in advanced GEP-NETs. The mixed outcomes affected the stock price.
Yahoo · Oct 13, 2026
Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival CrashesIn brief
Bristol Myers Squibb earned two Phase 3 wins in lung disease and cancer, yet the stock fell. The decline indicates investor caution despite the successes.
Yahoo · Oct 12, 2026
Monday's session: top gainers and losersIn brief
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
ChartMill · Oct 12, 2026
Bristol Myers Stock Tumbles on ‘Confounding’ Trial ResultsIn brief
Bristol Myers Squibb is investing $4.1 billion in radiopharmaceutical cancer drugs ahead of a 2028 patent cliff. The investment reflects a strategic bet on future revenue streams.
Yahoo · Oct 12, 2026

Latest on this name

Insights & deeper context

1 recent card — open any for the full deeper dive.

CompanyShort-termCautiousDays to weeksBenzingaCTNM JNJ

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

In brief

CTNM shares slid sharply after its Phase 2 depression trial failed to meet the primary endpoint, casting doubt on the drug’s future and impacting both companies’ outlooks.

Open card →

Company reports

Official filings (US SEC and linked cards)

No filings here yet

Official report cards for CTNM will show up here when available.

Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.